EQ-5D in Central and Eastern Europe: 2000–2015

Fanni Rencz, L. Gulácsi, Michael Drummond, Dominik Golicki, Valentina Prevolnik Rupel, Judit Simon, Elly A. Stolk, Valentin Brodszky, Petra Baji, Jakub Závada, Guenka Petrova, Alexandru Rotar, Márta Péntek

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries. Methods: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets. Results: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set. Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalQuality of Life Research
DOIs
Publication statusAccepted/In press - Jul 29 2016

Fingerprint

Slovenia
Eastern Europe
Poland
Hungary
Nutritional and Metabolic Diseases
Endocrine System Diseases
Bulgaria
Romania
Biomedical Technology Assessment
Slovakia
Quality-Adjusted Life Years
Austria
Czech Republic
Sample Size
Nervous System
Population
Databases
Costs and Cost Analysis

Keywords

  • Central and Eastern Europe
  • Cost-effectiveness analysis
  • EQ-5D
  • Health technology assessment
  • Health-related quality of life
  • Value sets

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Rencz, F., Gulácsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., ... Péntek, M. (Accepted/In press). EQ-5D in Central and Eastern Europe: 2000–2015. Quality of Life Research, 1-18. https://doi.org/10.1007/s11136-016-1375-6

EQ-5D in Central and Eastern Europe : 2000–2015. / Rencz, Fanni; Gulácsi, L.; Drummond, Michael; Golicki, Dominik; Prevolnik Rupel, Valentina; Simon, Judit; Stolk, Elly A.; Brodszky, Valentin; Baji, Petra; Závada, Jakub; Petrova, Guenka; Rotar, Alexandru; Péntek, Márta.

In: Quality of Life Research, 29.07.2016, p. 1-18.

Research output: Contribution to journalArticle

Rencz, F, Gulácsi, L, Drummond, M, Golicki, D, Prevolnik Rupel, V, Simon, J, Stolk, EA, Brodszky, V, Baji, P, Závada, J, Petrova, G, Rotar, A & Péntek, M 2016, 'EQ-5D in Central and Eastern Europe: 2000–2015', Quality of Life Research, pp. 1-18. https://doi.org/10.1007/s11136-016-1375-6
Rencz F, Gulácsi L, Drummond M, Golicki D, Prevolnik Rupel V, Simon J et al. EQ-5D in Central and Eastern Europe: 2000–2015. Quality of Life Research. 2016 Jul 29;1-18. https://doi.org/10.1007/s11136-016-1375-6
Rencz, Fanni ; Gulácsi, L. ; Drummond, Michael ; Golicki, Dominik ; Prevolnik Rupel, Valentina ; Simon, Judit ; Stolk, Elly A. ; Brodszky, Valentin ; Baji, Petra ; Závada, Jakub ; Petrova, Guenka ; Rotar, Alexandru ; Péntek, Márta. / EQ-5D in Central and Eastern Europe : 2000–2015. In: Quality of Life Research. 2016 ; pp. 1-18.
@article{f0a7324268544b9abee064be6403a1d8,
title = "EQ-5D in Central and Eastern Europe: 2000–2015",
abstract = "Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries. Methods: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets. Results: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 {\%}), neurologic (17 {\%}), musculoskeletal (15 {\%}) and endocrine, nutritional and metabolic diseases (13 {\%}) were the most frequently studied clinical areas. Overall, 112 (78 {\%}) of the studies reported EQ VAS results and 86 (60 {\%}) EQ-5D index scores, of which 27 (31 {\%}) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set. Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.",
keywords = "Central and Eastern Europe, Cost-effectiveness analysis, EQ-5D, Health technology assessment, Health-related quality of life, Value sets",
author = "Fanni Rencz and L. Gul{\'a}csi and Michael Drummond and Dominik Golicki and {Prevolnik Rupel}, Valentina and Judit Simon and Stolk, {Elly A.} and Valentin Brodszky and Petra Baji and Jakub Z{\'a}vada and Guenka Petrova and Alexandru Rotar and M{\'a}rta P{\'e}ntek",
year = "2016",
month = "7",
day = "29",
doi = "10.1007/s11136-016-1375-6",
language = "English",
pages = "1--18",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - EQ-5D in Central and Eastern Europe

T2 - 2000–2015

AU - Rencz, Fanni

AU - Gulácsi, L.

AU - Drummond, Michael

AU - Golicki, Dominik

AU - Prevolnik Rupel, Valentina

AU - Simon, Judit

AU - Stolk, Elly A.

AU - Brodszky, Valentin

AU - Baji, Petra

AU - Závada, Jakub

AU - Petrova, Guenka

AU - Rotar, Alexandru

AU - Péntek, Márta

PY - 2016/7/29

Y1 - 2016/7/29

N2 - Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries. Methods: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets. Results: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set. Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.

AB - Objective: Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries. Methods: An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets. Results: We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set. Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.

KW - Central and Eastern Europe

KW - Cost-effectiveness analysis

KW - EQ-5D

KW - Health technology assessment

KW - Health-related quality of life

KW - Value sets

UR - http://www.scopus.com/inward/record.url?scp=84979986642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979986642&partnerID=8YFLogxK

U2 - 10.1007/s11136-016-1375-6

DO - 10.1007/s11136-016-1375-6

M3 - Article

C2 - 27472992

AN - SCOPUS:84979986642

SP - 1

EP - 18

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

ER -